A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

2010276 citationsJournal Articlebronze Open Access

Authors

Brian M. Slomovitz · The University of Texas MD Anderson Cancer Center

Karen H. Lu · The University of Texas MD Anderson Cancer Center

Taren Johnston · The University of Texas MD Anderson Cancer Center

Robert L. Coleman · The University of Texas MD Anderson Cancer Center

Mark F. Munsell · The University of Texas MD Anderson Cancer Center

Russell R. Broaddus · The University of Texas MD Anderson Cancer Center

Abstract

Everolimus demonstrated encouraging single-agent CBR in pretreated patients with recurrent endometrioid EC. Future studies will evaluate this agent in combination with hormonal and/or cytotoxic therapy.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Beetle Biology and Toxicology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 116, Issue 23, pp. 5415-5419

DOI: 10.1002/cncr.25515

Field-Weighted Citation Impact: 11.49